FDA Approves Orkambi (lumacaftor/ivacaftor) for Cystic Fibrosis

ORKAMBI Generic Name: ivacaftor and lumacaftorDate of Approval: July 2, 2015Company: Vertex Pharmaceuticals Incorporated Treatment for: Cystic Fibrosis July 2, 2015 — The U.S. Food and Drug Administration today approved the first drug for cystic fibrosis directed at treating the cause of the disease in people who have two copies of a specific mutation. Orkambi (lumacaftor...

Read More

FDA Approves Entresto

July 7, 2015 — The U.S. Food and Drug Administration today approved Entresto(sacubitril/valsartan) tablets for the treatment of heart failure. The drug has been shown to reduce the rate of cardiovascular death and hospitalization related to heart failure. Entresto Generic Name: sacubitril and valsartanDate of Approval: July 7, 2015Company: Novartis Pharmaceuticals...

Read More

FDA Approves Odomzo

Odomzo (sonidegib) Capsules Company: Novartis Pharmaceuticals CorporationDate of Approval: July 24, 2015Treatment for: Basal Cell Carcinoma Odomzo is the second hedgehog pathway inhibitor approved for the treatment of basal cell carcinoma. The U.S. Food and Drug Administration (FDA) has approved Odomzo (sonidegib), an oral hedgehog pathway inhibitor for the...

Read More

FDA Approves Daklinza

Daklinza (daclatasvir) Tablets Company: Bristol-Myers Squibb CompanyDate of Approval: July 24, 2015Treatment for: Chronic Hepatitis C Daklinza in combination with sofosbuvir is the first 12-week, once-daily, all-oral treatment regimen for patients with chronic hepatitis C virus (HCV) genotype 3. The U.S. Food and Drug Administration (FDA) has approved Daklinza...

Read More